Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 1030-1036

  Okusaka, Takuji ^a   Kasugai, Hiroshi ^b   Shioyama, Yasukazu ^c   Tanaka, Katsuaki ^d   Kudo, Masatoshi ^e   Saisho, Hiromitsu ^f   Osaki, Yukio ^g   Sata, Michio ^h   Fujiyama, Shigetoshi ⁱ   Kumada, Takashi ^j   Sato, Keiko ^k   Yamamoto, Seiichiro ^l   Hinotsu, Shiro ^m   Sato, Tosiya ^k  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c Central Hospital   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f CHIBA UNIVERSITY   (Japan)

^g OSAKA RED CROSS HOSPITAL   (Japan)

^h KURUME UNIVERSITY   (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

^j OGAKI MUNICIPAL HOSPITAL   (Japan)

^k KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^l Center for Cancer Control and Information Services   (Japan)

^m UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

Gelatin sponge; Lipiodol emulsion; Overall survival; Survival benefit; Zinostatin stimalamer

Indexed keywords

GELATIN SPONGE; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MALEIC ANHYDRIDES; MIDDLE AGED; POLYSTYRENES; SURVIVAL RATE; ZINOSTATIN;

EID: 71849107086     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.09.004     Document Type: Article

References (26)

1. Bosch F.X., Ribes J., Cléries R., and Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9 (2005) 191-211
2. Lin D.Y., Liaw Y.F., Lee T.Y., and Lai C.M. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 94 (1988) 453-456
3. Pelletier G., Roche A., Ink O., Anciaux M.L., Derhy S., Rougier P., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990) 181-184
4. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
5. Pelletier G., Ducreux M., Gay F., Luboinski M., Hagège H., Dao T., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29 (1998) 129-134
6. Bruix J., Llovet J.M., Castells A., Montañá X., Brú C., Ayuso M.C., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27 (1998) 1578-1583
7. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
8. Llovet J.M., Real M.I., Montaña X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
9. Doffoel M, Vetter D, Bouche O, Bonnetain F, Abergel A, Fratte S, et al. Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients (Abstract). J Clin Oncol 2005;23:4006.
10. Cammà C., Schepis F., Orlando A., Albanese M., Shahied L., Trevisani F., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
11. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
12. Konno T., Maeda H., Iwai K., Tashiro S., Maki S., Morinaga T., et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19 (1983) 1053-1065
13. Okusaka T., Okada S., Ishii H., Ikeda M., Nakasuka H., Nagahama H., et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 55 (1998) 276-283
14. Liver Cancer Study Group of Japan. Criteria for evaluation of direct effects on hepatocellular carcinoma. Kanzo 35 (1994) 193-205
15. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2002) 421-430
16. Takayasu K., Arii S., Matsuo N., Yoshikawa M., Ryu M., Takasaki K., et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 175 (2000) 699-704
17. Okusaka T., Okada S., Ueno H., Ikeda M., Yoshimori M., Shimada K., et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology 58 (2000) 293-299
18. Japan society for cancer therapy: toxicity grading criteria of the Japan society for cancer therapy. J Jpn Soc Cancer Ther 1997;32:61-5.
19. World Health Organization. WHO handbook for reporting results of cancer treatment; offset publication 48. Geneva: World Health Organization; 1979.
20. Okusaka T., Okada S., Ueno H., Ikeda M., Iwata R., Furukawa H., et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 62 (2002) 228-233
21. Kirchhoff T.D., Bleck J.S., Dettmer A., Chavan A., Rosenthal H., Merkesdal S., et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 6 (2007) 259-266
22. Maeda H., Takeshita J., and Kanamaru R. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 14 (1979) 81-87
23. Maeda H., Takeshita J., Kanamura R., Sato H., Khatoh J., and Sato H. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and mater-soluble polymerconjugated protein. Gann 70 (1979) 601-606
24. Iwai K., Maeda H., and Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44 (1984) 2115-2121
25. Iwai K., Maeda H., Konno T., Matsumura Y., Yamashita R., Yamasaki K., et al. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 7 (1987) 321-327
26. Ikeda K., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., Tsubota A., et al. Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma. J Gastroenterol 35 (2000) 353-360